FK506 antigen is a novel macrolide with similar but more potent immunosuppressant activity than cyclosporine. FK506 is used for primary or rescue immunosuppression in patients after solid organ transplantation. Clinically relevant FK506 side effects are nephrotoxicity, neurotoxicity, diabetes mellitus and hypertension. Most of these side effects are more closely related to FK 506 blood levels than dosage; therefore therapeutic drug monitoring (TDM) of FK506 levels is a prerequisite for therapy. Whole blood is the matrix of choice for FK506 TDM. The whole blood target level range aimed for in clinical practice is between 3.0 and 20.0 ng/ml and depends on the patient’s liver function, the type of organ transplanted and the time after transplantation.
Our Abpromise guarantee covers the use of ab8316 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent concentration.|
ab8316 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"